Please login to the form below

Not currently logged in
Email:
Password:

Diagnostic breath-test analysis developed

Oxford Medical Diagnostics has developed a technology that enables diagnostics for various illnesses through breath analysis

Oxford Medical Diagnostics (OMD), which was formed in August 2010, has developed a unique technology that enables rapid, accurate and low-cost diagnostics for various illnesses, including diabetes, through breath analysis.

The company is currently prototyping a non-invasive point-of-care (at patient) diagnostic instrument to detect diabetes types 1 and 2, through identifying acetone in the breath. There are currently no major direct competitors in this area, while alternative methods include blood analysis which can be both painful and inconvenient.

The company's management team includes the CEO, Dr Tony Marchington, who founded Oxford Molecular, which reached an FTSE 250 valuation of £475m. This spin-off counts as one of the most successful entities linked to the University of Oxford and its intellectual property company, Isis Innovation.

OMD maintains close links with the University of Oxford and academics around the world, while it holds three important patents in plasma emission spectroscopy (PES – spectral analysis of light generated from a gaseous sample through which a small electric arc is passed) and exclusive licences to two further major patents through the University of Oxford.

10th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....